Cargando…

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruolan, Wright, Jonathan, Saggu, Parminder, Ait-Khaled, Mounir, Moodley, Riya, Parry, Chris M., Lutz, Thomas, Podzamczer, Daniel, Moore, Richard, Górgolas Hernández-Mora, Miguel, Kinder, Clifford, Wynne, Brian, van Wyk, Jean, Underwood, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/
https://www.ncbi.nlm.nih.gov/pubmed/37376649
http://dx.doi.org/10.3390/v15061350
_version_ 1785064688330997760
author Wang, Ruolan
Wright, Jonathan
Saggu, Parminder
Ait-Khaled, Mounir
Moodley, Riya
Parry, Chris M.
Lutz, Thomas
Podzamczer, Daniel
Moore, Richard
Górgolas Hernández-Mora, Miguel
Kinder, Clifford
Wynne, Brian
van Wyk, Jean
Underwood, Mark
author_facet Wang, Ruolan
Wright, Jonathan
Saggu, Parminder
Ait-Khaled, Mounir
Moodley, Riya
Parry, Chris M.
Lutz, Thomas
Podzamczer, Daniel
Moore, Richard
Górgolas Hernández-Mora, Miguel
Kinder, Clifford
Wynne, Brian
van Wyk, Jean
Underwood, Mark
author_sort Wang, Ruolan
collection PubMed
description The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (<1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, >99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144.
format Online
Article
Text
id pubmed-10300912
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103009122023-06-29 Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 Wang, Ruolan Wright, Jonathan Saggu, Parminder Ait-Khaled, Mounir Moodley, Riya Parry, Chris M. Lutz, Thomas Podzamczer, Daniel Moore, Richard Górgolas Hernández-Mora, Miguel Kinder, Clifford Wynne, Brian van Wyk, Jean Underwood, Mark Viruses Brief Report The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (<1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, >99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144. MDPI 2023-06-11 /pmc/articles/PMC10300912/ /pubmed/37376649 http://dx.doi.org/10.3390/v15061350 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Wang, Ruolan
Wright, Jonathan
Saggu, Parminder
Ait-Khaled, Mounir
Moodley, Riya
Parry, Chris M.
Lutz, Thomas
Podzamczer, Daniel
Moore, Richard
Górgolas Hernández-Mora, Miguel
Kinder, Clifford
Wynne, Brian
van Wyk, Jean
Underwood, Mark
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title_full Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title_fullStr Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title_full_unstemmed Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title_short Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
title_sort assessing the virologic impact of archived resistance in the dolutegravir/lamivudine 2-drug regimen hiv-1 switch study tango through week 144
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/
https://www.ncbi.nlm.nih.gov/pubmed/37376649
http://dx.doi.org/10.3390/v15061350
work_keys_str_mv AT wangruolan assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT wrightjonathan assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT sagguparminder assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT aitkhaledmounir assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT moodleyriya assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT parrychrism assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT lutzthomas assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT podzamczerdaniel assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT moorerichard assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT gorgolashernandezmoramiguel assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT kinderclifford assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT wynnebrian assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT vanwykjean assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144
AT underwoodmark assessingthevirologicimpactofarchivedresistanceinthedolutegravirlamivudine2drugregimenhiv1switchstudytangothroughweek144